The dose of inhaled corticosteroids in patients with COPD: when less is better

References

• AdeloyeDChuaSLeeCGlobal and regional estimates of COPD prevalence: Systematic review and meta-analysisJ Glob Health20155202041526755942
   PubMed Web of Science ®Google Scholar
• World Health OrganizationProjections of mortality and causes of death 2015 and 2030 Available from: http://www.who.int/healthinfo/globalburdendisease/projections/en/Accessed September 25, 2017
   Google Scholar
• López-CamposJLTanWSorianoJBGlobal burden of COPDRespirology2016211142326494423
   PubMed Web of Science ®Google Scholar
• HalpinDMDecramerMCelliBKestenSLiuDTashkinDPExacerbation frequency and course of COPDInt J Chron Obstruct Pulmon Dis2012765366123055714
   PubMed Web of Science ®Google Scholar
• AaronSDManagement and prevention of exacerbations of COPDBMJ2014349g523725245156
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseasePocket guide to COPD diagnosis, management, and prevention. A Guide for health care professionals2017 Available from: http://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdfAccessed May 3, 2017
   Google Scholar
• VestboJLangePPrevention of COPD exacerbations: medications and other controversiesERJ Open Res2015110001127730132
   PubMedGoogle Scholar
• MontuschiPPharmacological treatment of chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20061440942318044097
   PubMedGoogle Scholar
• SpencerPHananiaNAOptimizing safety of COPD treatments: role of the nurse practitionerJ Multidiscip Healthc20136536323459224
   PubMedGoogle Scholar
• BourbeauJBartlettSJPatient adherence in COPDThorax200863983183818728206
   PubMed Web of Science ®Google Scholar
• RestrepoRDAlvarezMTWittnebelLDMedication adherence issues in patients treated for COPDInt J Chron Obstruct Pulmon Dis20083337138418990964
   PubMedGoogle Scholar
• DecramerMJanssensWMiravitllesMChronic obstructive pulmonary diseaseLancet201237998231341135122314182
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• MiravitllesMCalleMSoler-CataluñaJJClinical phenotypes of COPD: identification, definition and implications for guidelinesArch Bronconeumol2012483869822196477
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• PandyaDPuttannaABalagopalVSystemic effects of inhaled corticosteroids: an overviewOpen Respir Med J20148596525674175
   PubMedGoogle Scholar
• SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• RennardSITashkinDPMcelhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• GershonASCampitelliMACroxfordRCombination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary diseaseJAMA2014312111114112125226477
   PubMed Web of Science ®Google Scholar
• HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest2003124383484312970006
   PubMed Web of Science ®Google Scholar
• FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsRespir Med200810281099110818614347
   PubMed Web of Science ®Google Scholar
• AnzuetoAFergusonGTFeldmanGEffect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesCOPD20096532032919863361
   PubMedGoogle Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• KardosPWenckerMGlaabTVogelmeierCImpact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2007175214414917053207
   PubMed Web of Science ®Google Scholar
• WedzichaJASinghDVestboJExtrafine beclomethasone/formoterol in severe COPD patients with history of exacerbationsRespir Med201410881153116224953015
   PubMed Web of Science ®Google Scholar
• KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database Syst Rev201433CD010844
   Google Scholar
• NanniniLJCatesCJLassersonTJPoolePCombined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20074CD006829
   PubMed Web of Science ®Google Scholar
• di MartinoMAgabitiNCasciniSThe effect on total mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: a real practice analysis in ItalyCOPD201613329330226514912
   PubMedGoogle Scholar
• CosioBGSorianoJBLópez-CamposJLDefining the asthma– COPD overlap syndrome in a COPD cohortChest20161491455226291753
   PubMed Web of Science ®Google Scholar
• SuzukiMMakitaHKonnoSAsthma-like features and clinical course of chronic obstructive pulmonary disease. An analysis from the Hokkaido COPD Cohort StudyAm J Respir Crit Care Med2016194111358136527224255
   PubMed Web of Science ®Google Scholar
• TashkinDPRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
   PubMed Web of Science ®Google Scholar
• WelteTMiravitllesMHernandezPEfficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009180874175019644045
   PubMed Web of Science ®Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20143CD010115
   PubMed Web of Science ®Google Scholar
• SinDDTashkinDZhangXBudesonide and the risk of pneumonia: a meta-analysis of individual patient dataLancet2009374969171271919716963
   PubMed Web of Science ®Google Scholar
• VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet2017389100821919192928385353
   PubMed Web of Science ®Google Scholar
• SuissaSPatenaudeVLapiFErnstPInhaled corticosteroids in COPD and the risk of serious pneumoniaThorax201368111029103624130228
   PubMed Web of Science ®Google Scholar
• ErnstPGonzalezAVBrassardPSuissaSInhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumoniaAm J Respir Crit Care Med2007176216216617400730
   PubMed Web of Science ®Google Scholar
• GarchaDSThurstonSJPatelARChanges in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPDThorax201267121075108022863758
   PubMed Web of Science ®Google Scholar
• BrassardPSuissaSKezouhAErnstPInhaled corticosteroids and risk of tuberculosis in patients with respiratory diseasesAm J Respir Crit Care Med2011183567567820889902
   PubMed Web of Science ®Google Scholar
• SonnappaSMartinRIsraelERisk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroidsPLoS One2017126e017811228617814
   PubMed Web of Science ®Google Scholar
• LipworthBJSystemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysisArch Intern Med1999159994195510326936
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAssessment report EMA/330021/2016. Inhaled corticosteroids (ICS) containing medical products indicated in the treatment of chronic obstructive pulmonary disease (COPD)London, UKEuropean Medicines Agency2016
   Google Scholar
• LokeYKCavallazziRSinghSRisk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studiesThorax201166869970821602540
   PubMed Web of Science ®Google Scholar
• LapiFKezouhASuissaSErnstPThe use of inhaled corticosteroids and the risk of adrenal insufficiencyEur Respir J2013421798623060630
   PubMed Web of Science ®Google Scholar
• SuissaSKezouhAErnstPInhaled corticosteroids and the risks of diabetes onset and progressionAm J Med2010123111001100620870201
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• KannerREAnthonisenNRConnettJELung Health Study Research GroupLower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health studyAm J Respir Crit Care Med2001164335836411500333
   PubMed Web of Science ®Google Scholar
• ConnorsAFJrDawsonNVThomasCOutcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)Am J Respir Crit Care Med19961544 Pt 19599678887592
   PubMed Web of Science ®Google Scholar
• FesticEScanlonPDIncident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids?Am J Respir Crit Care Med2015191214114825409118
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• PapiAVestboJFabbriLExtrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialLancet2018391101251076108429429593
   PubMed Web of Science ®Google Scholar
• LipworthBJAirway and systemic effects of inhaled corticosteroids in asthma: dose response relationshipPulm Pharmacol19969119278843506
   PubMedGoogle Scholar
• KankaanrantaHLahdensuoAMoilanenEBarnesPJAdd-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive reviewRespir Res200451715509300
   PubMed Web of Science ®Google Scholar
• AdamsNPJonesPWThe dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviewsRespir Med200610081297130616806876
   PubMed Web of Science ®Google Scholar
• DahlRSystemic side effects of inhaled corticosteroids in patients with asthmaRespir Med200610081307131716412623
   PubMed Web of Science ®Google Scholar
• PriceDYawnBBrusselleGRossiARisk-to-benefit ratio of inhaled corticosteroids in patients with COPDPrim Care Respir J20132219210023135217
   PubMedGoogle Scholar
• SabroeIPostmaDHeijinkIDockrellDHThe yin and the yang of immunosuppression with inhaled corticosteroidsThorax201368121085108723929790
   PubMed Web of Science ®Google Scholar
• RodrigoGJCastro-RodriguezJAPlazaVSafety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic reviewChest200913641029103819633090
   PubMed Web of Science ®Google Scholar
• YawnBPLiYTianHZhangJArconaSKahlerKHInhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysisInt J Chron Obstruct Pulmon Dis2013829530423836970
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKRisk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and updateCurr Opin Pulm Med201016211812219926996
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• NadeemNJTaylorSJEldridgeSMWithdrawal of inhaled corticosteroids in individuals with COPD – a systematic review and comment on trial methodologyRespir Res20111210721838890
   PubMed Web of Science ®Google Scholar
• van der ValkPMonninkhofEvan der PalenJZielhuisGvan HerwaardenCEffect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE studyAm J Respir Crit Care Med2002166101358136312406823
   PubMed Web of Science ®Google Scholar
• WoutersEFPostmaDSFokkensBWithdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trialThorax200560648048715923248
   PubMed Web of Science ®Google Scholar
• KunzLIZPostmaDSKloosterKRelapse in FEV1 decline after steroid withdrawal in COPDChest2015148238939625836351
   PubMed Web of Science ®Google Scholar
• SuissaSRossiAWeaning from inhaled corticosteroids in COPD: the evidenceEur Respir J20154651232123526521271
   PubMed Web of Science ®Google Scholar
• WatzHTetzlaffKWoutersEFBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med20164539039827066739
   PubMed Web of Science ®Google Scholar
• CosioMBaraldoSSaettaMInhaled glucocorticoids and COPD exacerbationsN Engl J Med2015372192
   Google Scholar
• YawnBPSuissaSRossiAAppropriate use of inhaled corticosteroids in COPD: the candidates for safe withdrawalNPJ Prim Care Respir Med2016261606827684954
   PubMed Web of Science ®Google Scholar
• ChapmanKRHurstJRFrentSMLong-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trialAm J Respir Crit Care Med2018198332933929779416
   PubMed Web of Science ®Google Scholar
• BafadhelMPetersonSDe BlasMAPredictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trialsLancet Respir Med20186211712629331313
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• CrimCCalverleyPMAndersonJAPneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study resultsEur Respir J200934364164719443528
   PubMed Web of Science ®Google Scholar
• SharafkhanehASouthardJGGoldmanMUryniakTMartinUJEffect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized studyRespir Med2012106225726822033040
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• BassamMMayankVSteroids in asthma: friend or foeQianXGlucocorticoids. New recognition of our familiar friend IntechOpen2012569592
   Google Scholar